TNGX - Tango Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$45.91
DETAILS
HIGH:
$69.00
LOW:
$24.00
MEDIAN:
$40.00
CONSENSUS:
$45.91
UPSIDE:
105.05%
Institutional Holders (13F)
| GURU | SHARES | VALUE | WEIGHT % | SHARES CHG | ACTION |
|---|---|---|---|---|---|
| Wood | 298,339 | $9.3M | 0.0% | -235,598 | DECREASED |
| Cooperman | 0 | $0 | -- | -- | SOLD |
| Greenblatt | 0 | $0 | -- | -19,137 | SOLD |
| Laffont | 0 | $0 | -- | -12,557 | SOLD |
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-08-03 | Crystal Adam | officer: President, R&D | SELL | 21,733 | $27.35 | $594K |
| 2026-08-03 | Crystal Adam | officer: President, R&D | SELL | 5,267 | $26.79 | $141K |
| 2026-08-03 | Crystal Adam | officer: President, R&D | M-Exempt | 27,000 | $5.20 | $140K |
| 2026-07-01 | Crystal Adam | officer: President, R&D | SELL | 7,371 | $30.25 | $223K |
| 2026-07-01 | Crystal Adam | officer: President, R&D | M-Exempt | 27,000 | $5.20 | $140K |
| 2026-07-01 | Crystal Adam | officer: President, R&D | SELL | 19,629 | $29.34 | $576K |
| 2026-06-19 | Azelby Robert | director | A-Award | 5,740 | -- | -- |
| 2026-06-19 | Azelby Robert | ? | -- | -- | -- | |
| 2026-06-19 | Azelby Robert | director | A-Award | 35,910 | $27.97 | $1.0M |
| 2026-06-05 | Lee Sung | director | A-Award | 570 | -- | -- |
| 2026-06-05 | Lee Sung | director | A-Award | 3,570 | $20.22 | $72K |
| 2026-06-05 | Ketchum John B | director | A-Award | 25,000 | $20.22 | $506K |
| 2026-06-05 | Ketchum John B | director | A-Award | 4,000 | -- | -- |
| 2026-06-05 | Rothenberg Mace | director | A-Award | 25,000 | $20.22 | $506K |
| 2026-06-05 | Rothenberg Mace | director | A-Award | 4,000 | -- | -- |
| 2026-06-05 | Calhoun Lesley Ann | director | A-Award | 25,000 | $20.22 | $506K |
| 2026-06-05 | Calhoun Lesley Ann | director | A-Award | 4,000 | -- | -- |
| 2026-06-01 | Crystal Adam | officer: President, R&D | M-Exempt | 27,000 | $5.20 | $140K |
| 2026-06-01 | Crystal Adam | officer: President, R&D | SELL | 20,860 | $23.06 | $481K |
| 2026-06-01 | Crystal Adam | officer: President, R&D | SELL | 6,140 | $22.25 | $137K |
| 2026-05-01 | Gall Matthew | officer: Chief Financial Officer | A-Award | 240,000 | $20.98 | $5.0M |
| 2026-05-01 | Gall Matthew | officer: Chief Financial Officer | A-Award | 40,000 | -- | -- |
| 2026-05-01 | Crystal Adam | officer: President, R&D | SELL | 25,900 | $21.19 | $549K |
| 2026-05-01 | Crystal Adam | officer: President, R&D | SELL | 1,100 | $22.00 | $24K |
| 2026-05-01 | Crystal Adam | officer: President, R&D | M-Exempt | 27,000 | $5.20 | $140K |